Advent Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Advent Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,000	Closed	-$2.92M	–	233
2023 Q1	$2.92M	Buy	+30,000	New	+$3.11M	0.06%	160
2017 Q1	–	Sell	-503	Closed	-$34K	–	271
2016 Q4	$34K	Buy	503 +400	+388%	+$34.4K	﹤0.01%	239
2016 Q3	$6K	Sell	103 -597	-85%	-$56.2K	﹤0.01%	473
2016 Q2	$47K	Buy	700 +380	+119%	+$32.3K	﹤0.01%	410
2016 Q1	$14K	Buy	320 +70	+28%	+$5.7K	﹤0.01%	400
2015 Q4	$65K	Sell	250 -720	-74%	-$75.2K	﹤0.01%	396
2015 Q3	$130K	Buy	970 +670	+223%	+$89.5K	﹤0.01%	430
2015 Q2	$58K	Sell	300 -305	-50%	-$37.8K	﹤0.01%	447
2015 Q1	$271K	Sell	605 -794	-57%	-$84.1K	﹤0.01%	408
2014 Q4	$146K	Buy	+1,399	New	+$116K	﹤0.01%	425

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Advent Capital Management's BMRN Position: Q1 2021 in Review

Advent Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 4,520 shares — an estimated $396K sold.

Advent Capital Management first reported a position in BMRN in Q2 2013 and held it in 16 quarters. The position peaked at $6.62M in Q1 2015. 531 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

Advent Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Advent Capital Management sold 4,520 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $396K.
Advent Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 16 quarters.
Advent Capital Management's BioMarin Pharmaceuticals position peaked at $6.62M in Q1 2015.
531 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on Advent Capital Management's 13F filing for Q1 2021, filed 17 May 2021.